SCHEMBL5734501

SCHEMBL5734501

CCOP(=O)(O)CC(=O)c1cccc(OCCc2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
NR1H4 Q96RI1 1/20 0.46
LMNA P02545 1/20 0.44
MAPK1 P28482 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAOB P27338 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
FFAR1 O14842 1/20 0.44
PTPN1 P18031 1/20 0.44
MEN1 O00255 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
NR4A2 P43354 1/20 0.43
ALDH1A1 P00352 2/20 0.43
SMPD1 P17405 1/20 0.43
HTT P42858 1/20 0.42
NPC1 O15118 1/20 0.41
POLB P06746 1/20 0.41
CASP3 P42574 1/20 0.41
RAB9A P51151 1/20 0.41
SENP8 Q96LD8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490457 0.88 MAOB (0.59) KMT2ANR1H4MAOBSMN1; SMN2PTPN1
SCHEMBL5734272 0.86 SMPD1 (0.53) KMT2ANR1H4LMNAMAPK1L3MBTL1
SCHEMBL5733422 0.85 RAB9A (0.51) KMT2ANR1H4LMNAMAPK1L3MBTL1
SCHEMBL5732744 0.84 MRGPRX4 (0.56) LMNAMAOBSMN1; SMN2PTPN1NR4A2
SCHEMBL5733094 0.83 ERCC5 (0.53) KMT2ALMNASMN1; SMN2MEN1ALDH1A1
SCHEMBL5734492 0.82 NR1H4 (0.48) KMT2ANR1H4LMNAMAOBSMN1; SMN2
SCHEMBL6486933 0.82 KMT2A (0.43) KMT2ANR1H4LMNAMAPK1L3MBTL1
SCHEMBL5734543 0.81 LMNA (0.42) LMNASMN1; SMN2PTPN1POLB
SCHEMBL5732673 0.80 CES2 (0.51) KMT2ASMN1; SMN2MEN1ALDH1A1NPC1
SCHEMBL5733025 0.79 KAT6A (0.43) LMNASMN1; SMN2NPC1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1409455-B1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2006-01-04 EP disclosed
US-6900336-B2 8-aza-11-deoxy prostaglandin analogues SYNTEX (U.S.A.) LLC (US) 2005-05-31 US disclosed
EP-1409455-A1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-21 EP disclosed
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction SYNTEX (U.S.A.) LLC 2003-06-26 US disclosed
WO-2003008377-A1 PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction PTGER4, FFAR4, PTGER1 KMT2A 3518/4885NR1H4 16/4885LMNA 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.